Medical directors of life and disability companies need to be aware of CRISPR technology and how it has beneficial and potential detrimental impacts to our industry. Clustered Interspaced Short Palindromic Repeats (CRISPR) is only 7 years old, but we are already seeing human clinical trials underway with this powerful but elegantly simple gene editing technology. It has the potential to revolutionize medicine and will bring human beings into an ethical debate like none other including the creation of life itself. This article will give the background of the development of this new technology, the ways that it is currently being used and the many areas of technology and medicine that will be transformed by its use. This article will also touch on the ethical debate that will need to be addressed as this technology becomes more readily available and used in research labs around the globe.

You do not currently have access to this content.